Type 2 diabetes mellitus (T2DM) is the common form of diabetes accounting for 90 per cent of cases worldwide and is continuously increasing. Over the past 30 years, the status of diabetes has changed from being considered as a mild disorder of the old age to one of the major causes of morbidity and mortality affecting the young and middle aged people. It is estimated that approximately 285 million people worldwide, or 6.6 per cent in the age group 20-79 yr, will have diabetes by the end of 2010, 70 per cent of whom live in low- and middle-income countries. This number is expected to increase by more than 50 per cent in the next 20 years if preventive programmes are not put in place. Some 438 million people, or 7.8 per cent of the adult population, are projected to have diabetes by 2030[@ref1]. The largest increases will take place in the regions dominated by developing economies as is evident from the alarming number of diabetic patients in India[@ref1][@ref2].

T2DM occurs primarily due to a 'high blood sugar level' resulting in hyperglycaemia, glycosuria, dyslipidaemia, high levels of low density lipoproteins (LDL) and low levels of high density lipoproteins (HDL). If remained uncontrolled, T2DM may lead to various complications such as abdominal obesity, hypertension, atherosclerosis, stroke, coronary heart disease, *etc*. However, the mechanisms involved in determination of the risk of developing diabetes are still not known clearly. It has been established that T2DM has a genetic component and several candidate genes are responsible for inducing susceptibility to this disease such as adiponectin gene (*ADIPOQ*), *TCF7L20*, β3 adrenergic receptor (β3AR) gene and many more[@ref3]--[@ref8]. There have been reports of a gene coding for a macrophage receptor, *CD36* which has shown association with hypertension and metabolic syndrome in the Caucasian and African-American populations, respectively[@ref9][@ref10].

CD36 is a 88 kDa integral transmembrane protein, one of the most important molecules found on the surface of many cells in vertebrates and has the ability to endocytose oxidized LDL (OxLDL)[@ref11][@ref12]. Several studies suggested the role of CD36 as an important regulator of the metabolic pathways involved in insulin resistance[@ref13]--[@ref15]. The pathophysiology of human CD36 deficiency in metabolic syndrome and atherogenesis has been explained[@ref16]. Highly oxidized lipoproteins can be rapidly taken up by macrophages to give rise to foam cells, cholesterol engorged cells that are hallmark of early atherosclerotic lesions. The increased fatty acid availability can induce insulin resistance if the capacity of adipose tissue to store triglycerides and/or that of muscle to oxidize FA is exceeded[@ref17]. A recent report has shown that alteration in CD36 levels might be involved in the development of diet-induced insulin-resistance in mice[@ref18].

*CD36* gene has 15 exons extending over 32 kb on chromosome 7q11.2[@ref19][@ref20]. It has been reported that genetic factors like single nucleotide polymorphisms (SNPs) in the *CD36* gene are significantly associated with T2DM[@ref10][@ref21]--[@ref23] while exonic deletions such as exons 4, 9, 11, 12 and 13 in the *CD36* gene lead to its deficiency[@ref24]--[@ref26]. Deletion of exons 3, 4 and 5 in *CD36* gene has been studied in the Japanese population[@ref24] while significant alteration in the activity of CD36 gene has been shown to occur due to small nucleotide deletions of 10, 12, 16 and 29 bps[@ref9][@ref25]. Exon 3 contains the last 89 nucleotides of the 5'-untranslated region, encodes the N-terminal cytoplasmic and transmembrane domains. Deletion of the two non-coding exons 1 and 2 along with third exon results in no expression of CD36 protein. Exons 4 and 5 encode amino acids 41-94 and 94-143, respectively which constitute potential N-glycosylation sites. The skipping of these exons results in a defect of the ligand binding site of CD36 protein[@ref20].

CD36 deficiency can be divided into two subgroups, type I in which neither platelets nor monocytes/macrophages express CD36, and in type II monocytes/macrophages express CD36 but platelets do not. Two important mutations in *CD36* gene responsible for CD36 deficiency are SNP T/C at nt 478 of *CD36* (Exon 4) and a dinucleotide deletion (delAC in Exon 5)[@ref27]--[@ref29]. The 478C\>T polymorphism (proline-90 serine) predominates in the type I and type I1 CD36 deficiency[@ref24][@ref28] via defects in post-translational modification, while the dinucleotide deletion causes a frameshift mutation leading to the appearance of a translation stop codon and a marked reduction in the level of CD36 mRNA.

The role of *CD36* gene in lipid metabolism and T2DM susceptibility prompted us to take up this study on *CD36* gene status in the north Indian population. We screened the deletion of exons 3, 4 and 5 and the polymorphisms viz. 478C\>T SNP in exon 4 and a delAC in exon 5 of the *CD36* gene.

Material & Methods {#sec1-1}
==================

*Sample collection*: The study protocol was approved by the institutional ethical committee of Chatrapati Sahuji Maharaj Medical University (CSMMU), Lucknow, and the study was performed during March-November, 2009. Written informed consent was obtained from all participants. Blood samples were collected randomly from 300 patients (173 males and 127 females) from the Diabetic Clinic of Medicine OPD, CSMMU, Lucknow and their clinical details, family history of diabetes and associated complications were recorded. Control samples (n=100) were collected from healthy staff members and students of University of Lucknow. The screening and management of patients were done as per American Diabetes Association guidelines[@ref30]. Criteria for patients' participation included fasting plasma glucose (FPG) ≥126 mg/dl or a 2 h blood glucose level of ≥200 mg/dl after a 75 g oral glucose load (oral glucose tolerance test). Individuals with a history of major illness were excluded. Normal individuals were included on the basis of normal FPG of 70-109 mg/dl or random plasma glucose (RPG) 110-199 mg/dl.

*Biochemical parameters*: Two ml blood samples were equally distributed in two vials, one ml in 0.5M EDTA and the other in a plain vial for DNA extraction and biochemical estimations respectively. Serum was collected from the blood in plain vials after centrifugation for 10 min at 2655 g at 4°C. Estimations of plasma glucose (mg/dl), serum insulin (mg/dl) and lipid profile (total serum cholesterol, TC; High density lipoprotein-cholesterol, HDL-C and serum triglycerides, TG) were done using commercially available Ecoline kits (Merck, India) by double beam spectrophotometer (Shimadzu, Japan) at 550 nm (TGL-C), 510 nm (S. creatinine), 500 nm (TC) and 560 nm (HDL-C). Height, weight and waist circumference were measured to calculate body mass index (BMI) and waist hip ratio (WHR). Systolic and diastolic (disappearance of Korotkoff sound, phase V) blood pressures were measured in the sitting position with an appropriately sized cuff after a 5 min rest. Clinical details of patients and control subjects were recorded ([Table I](#T1){ref-type="table"}).

###### 

Clinical parameters of T2DM patients and control subjects
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*DNA extraction and deletion analysis*: DNA was extracted from blood samples of T2DM patients using the salting out method[@ref31] with slight modifications. Lysis was followed by proteinase K buffer (0.375M NaCl, 0.012M EDTA) and SDS (10%) treatment. After frothing, cold 5M NaCl was added followed by phenol-chloroform extraction. DNA was checked on 0.8-1 per cent agarose gel. The quantity of DNA was estimated using double beam UV-visible spectrophotometer and quality was checked by measuring A~260~/A~280~. Exons 3 (nt 1722 to 1986), 4 (nt 12038 to 12404) and 5 (nt 17779 to 17977) of *CD36* gene were amplified by polymerase chain reaction (PCR) using respective primers using Master Cycler ep Gradient (Eppendorf, USA)[@ref24]. The primer sequences and PCR conditions are shown in [Table II](#T2){ref-type="table"}. PCR was performed for 30 cycles using 0.5U Taq polymerase, 10 pmol/μl of each primer, and 200μM dNTP in 25μl reaction volume. The PCR products were checked on 1.5 per cent agarose gel along with 50 and 100 bp markers. The gels were documented and analyzed.

###### 

Primer sequences, nucleotide (nt) positions, PCR conditions and product sizes of exons
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*Genotype analysis*: Two polymorphisms in CD36 gene responsible for exon deletions viz. 478C\>T in exon 4 and a dinucleotide deletion (delAC) in exon 5 were analyzed in T2DM patients and control subjects by polymerase chain reaction and restriction fragment length polymorphisms (PCR-RFLP)[@ref24][@ref27]--[@ref29]. The primers used were as shown in [Table II](#T2){ref-type="table"}and the restriction enzymes used were *Cfr131* and *BoxI*, identified by NEB cutter software ([www.tools.neb.com/NEB cutter 2](www.tools.neb.com/NEBcutter2)) for 478C\>T and delAC respectively. The PCR amplicons and digested products were resolved on 10 per cent polycrylamide gels (PAGE), stained with ethidium bromide and documented in Gel Doc (Vilber Lourmat, France).

*Statistical analysis*: Statistical analysis was applied to biochemical data using SPSS software ([www.spss.com](www.spss.com)) (v15.0). Mean ± SD (standard deviation) of all clinical parameters and diabetic duration was calculated in each age group (≤40, 41-59 and ≥ 60 yr) as well as in BMI groups (\<18.5; 18.5-25 and \>25 kg/m^2^). *P* values were calculated by 2x2 contingency table using paired t-test. All *P* values were two sided and *P*\<0.05, was considered significant.

Results & Discussion {#sec1-2}
====================

The average age of the patients was 48.61±9.96 yr and their fasting and post-prandial glucose levels were 165.40 ± 69.65 and 266.40 ± 97.04 mg/dl, respectively. The average systolic BP was slightly elevated (135.22 ± 19.35 mmHg) and the mean diastolic pressure was almost normal (84.27 ± 10.77 mmHg). Total cholesterol (233.98 ± 26.13 mm/dl) and LDL-C (168.61 ± 26.13 mmHg) levels were slightly raised and HDL-C was low (42.21 ± 4.19 mmHg). However, no significant difference was observed in BMI, WHR, triglycerides and serum creatinine levels between the T2DM and control groups ([Table I](#T1){ref-type="table"}).

The PCR products of exons 3 (265 bp), 4 (358 bp) and 5 (199 bp) are shown in [Fig. 1](#F1){ref-type="fig"}. Exonic deletion was observed neither in patients nor controls. In our study population all individuals (patients and controls) were found to be homozygous 'CC' and -/- for 478C\>T and delAC polymorphisms respectively ([Fig. 2](#F2){ref-type="fig"}).

![Agarose gels showing PCR products of (**A**) Exon 3, (**B**) Exon 4, (**C**) Exon 5, Lane M:100 and 50 bp ladder.](IJMR-134-107-g003){#F1}

![Gel showing 478C\>T SNP in exon 4, lane M, 50 bp ladder; lane UD, undigested PCR product; lanes 1-4, 5-8, PCR products digested with *Cfr131* showing CC genotype. (B). Gel picture of delAC in exon 5, lane M, 50 bp ladder; lane UD undigested PCR product; lanes 1-3, 4, 5-8, *Box I* digested PCR products showing -/- genotype.](IJMR-134-107-g004){#F2}

CD36, being an important receptor molecule for modified lipoproteins, plays an important role in the regulation of lipid metabolism. Studies have shown its involvement in diverse disorders such as insulin resistance, dyslipidaemia, hyperlipidaemia, atherosclerosis[@ref32][@ref33] and T2DM[@ref21][@ref22]. Lipid abnormalities in CD36 deficiency might depend on the presence of diabetes since the total cholesterol and triglyceride levels in diabetic CD36 deficient patients were higher than in control subjects and non-diabetic CD36-deficient patients[@ref33]. Several kinds of *CD36* gene mutations have been reported in CD36-deficient patients[@ref25]. A dinucleotide (AC) deletion in exon 5 of *CD36* gene led to a frameshift mutation resulting in a stop codon[@ref24] while the insertion of nucleotide A at position 1159 led to the abnormal splicing in mRNA resulting in skipping of exons 4, 9, 11 in type 1 CD36 deficient subjects[@ref26]. However, our study did not show deletion of exons 3, 4 and 5 of the *CD36* gene in north Indian T2DM patients as well as controls. All individuals tested for 478C\>T and delAC polymorphisms were 'CC' and -/- homozygotes respectively. This suggests that in our population *CD36* exonic deletion is not prevalent; as a result deficiency of CD36 protein is not evident.

CD36 expression in monocytes is upregulated by oxidized low density lipoprotein (Ox-LDL), whose levels increase in case of T2DM, hyperglycaemia and related atherosclerosis[@ref15]. CD36 deficiency can promote defective insulin action (resistance) and disordered fatty acid metabolism in spontaneous hypertension[@ref34].

Although the molecular aspects of CD36 and its complications are not very clear, there have been attempts to study its polymorphisms and their association with T2DM. *CD36* genotype was identified as a fundamental determinant of myocardial long chain fatty-acid uptake[@ref13][@ref35][@ref36]. We have recently reported that one of the several SNPs in the *CD36* gene (rs1761667, G\>A) shows a significant association with T2DM in the north Indian population[@ref37]. This provides a lead for the *CD36* genotypes and their association with T2DM. Our findings are in support of the data obtained from other populations such as the -178 A/C SNP promoter mutation in the *CD36* gene in the French population[@ref21][@ref22] and a *CD36* nonsense mutation in caucasians[@ref21]. It appears that *CD36* variants vary in different racial and ethnic populations. The *CD 36* gene polymorphisms in selected north Indian population in this study did not show any variation but since the *CD36* molecule has a definite role to play in T2DM, it will be interesting to determine the genetic variants at the *CD36* locus and their association with insulin sensitivity, diabetes, and atherosclerosis in our population.
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